Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 4-Benzyloxyaniline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 11/20 | 0.96 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.96 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.96 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.64 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.64 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.64 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.64 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.64 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.58 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.96 |
| ▸ | F2 | P00734 | 1/20 | 0.65 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Benzyloxyaniline SCHEMBL171449 | 0.98 | MAOB (1.00) | MAOBRAB9AGAAMAPTMAOA | |
| 4-Benzyloxyaniline SCHEMBL5376217 | 0.96 | MAOB (0.96) | MAOBRAB9AGAAMAPTMAOA | |
| 4-Benzyloxyaniline SCHEMBL8216099 | 0.93 | MAOB (0.82) | MAOBRAB9AGAAMAPTMAOA | |
| SCHEMBL6733465 | 0.92 | MAOB (0.89) | MAOBRAB9AGAAMAPTMAOA | |
| SCHEMBL5045790 | 0.92 | MAOB (0.89) | MAOBRAB9AGAAMAPTMAOA | |
| SCHEMBL323938 | 0.89 | MAOB (0.84) | MAOBRAB9AGAAMAPTMAOA | |
| 4-Benzyloxyaniline SCHEMBL5571271 | 0.89 | MAOB (0.83) | MAOBRAB9AGAAMAPTMAOA | |
| SCHEMBL31542030 | 0.87 | MAOB (0.80) | MAOBRAB9AGAAMAPTMAOA | |
| SCHEMBL5121663 | 0.87 | MAOB (0.80) | MAOBRAB9AGAAMAPTMAOA | |
| SCHEMBL339813 | 0.87 | LMNA (0.82) | MAOBRAB9AGAAMAPTMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153655-B | Novel N-acylurea derivatives and compositions comprising the same for preventing or treating cardiovascular diseases | 高丽大学校产学协力团 | 2022-09-30 | — | — | CN | claimed |
| US-20200131431-A1 | CHEMICAL ADDITIVES AND SURFACTANT COMBINATIONS FOR FAVORABLE WETTABILITY ALTERATION AND IMPROVED HYDROCARBON RECOVERY FACTORS | ALCHEMY SCIENCES INC (US) | 2020-04-30 | — | — | US | claimed |
| CN-106810487-B | Efficient preparation method of bazedoxifene | 四川科伦药物研究院有限公司 | 2020-03-17 | — | — | CN | claimed |
| EP-2118058-B9 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | ZENTIVA KS (CZ) | 2012-03-28 | — | — | EP | claimed |
| EP-2118058-B1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | ZENTIVA KS (CZ) | 2011-06-08 | — | — | EP | claimed |
| CN-102001955-A | Method for synthesizing 4-benzyloxy aniline hydrochloride | XUZHOU RUISAI TECHNOLOGY INDUSTRY CO LTD | 2011-04-06 | — | — | CN | claimed |
| US-20100087661-A1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | ZENTIVA K.S. (CZ) | 2010-04-08 | — | — | US | claimed |
| EP-2118058-A1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | Zentiva, k.s. (CZ) | 2009-11-18 | — | — | EP | claimed |
| WO-2008098527-A1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | ZENTIVA A.S. (CZ) | 2008-08-21 | — | — | WO | claimed |
| EP-0044536-A1 | Plant growth regulators and their use | J.T. Baker Chemical Co. (US) | 1982-01-27 | — | — | EP | claimed |
| JP-9087253-A | — | — | None | — | — | JP | disclosed |
| US-20240254096-A1 | ULTRAVIOLET AND VISIBLE RADIATION ABSORBING COMPOUNDS | ELKIMIA INC (CA) | 2024-08-01 | — | — | US | disclosed |
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240182475-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH HYPERMINERALIZATION | Université de Lausanne (CH) | 2024-06-06 | — | — | US | disclosed |
| EP-4367094-A1 | ULTRAVIOLET AND VISIBLE RADIATION ABSORBING COMPOUNDS | Elkimia Inc. (CA) | 2024-05-15 | — | — | EP | disclosed |
| US-4062864-A | ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-3959309-A | ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1976-05-25 | — | — | US | disclosed |
| US-3947434-A | 9-(P-phenylazoanilino)-7-methyl-1H-imidazo[4,5-f]quinolines | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-03-30 | — | — | US | disclosed |
| US-3946049-A | 5-PHENYL-2-FURAMIDOXIMES | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-03-23 | — | — | US | disclosed |
| JP-H00987253-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087661-A1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | CYP19A1, CYP17A1, SHBG | MAOB 85/4885GAA 4380/4885MAOA 110/4885 |
| US-20240182475-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH HYPERMINERALIZATION | CTH, CBS, GAA | MAOB 1012/4885GAA 3/4885MAOA 1276/4885 |
| US-20240254096-A1 | ULTRAVIOLET AND VISIBLE RADIATION ABSORBING COMPOUNDS | ERCC1, ERCC4, ERCC5 | MAOB 1316/4885GAA 2044/4885MAOA 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.